TABLE 35Measures of cognition in included studies: head-to-head comparisons

StudySubgroupOutcomeTypeRivastigmineDonepezilp-value
nMean (SD)nMean (SD)
Bullock et al. (2005)148LOCF analysisMMSE – 104 weeksMC471−2.35 (6.51)484−2.85 (6.6)0.089,a 0.106b
SIB – 104 weeksMC471−9.3 (23.9)483−9.91 (24.2)0.609,a 0.738b

MC, mean change.

a

Analysis of covariance (ANCOVA), covarying country, MMSE category and baseline score.

b

Wilcoxon's rank-sum test.

From: 3, Assessment of clinical effectiveness

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.